Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

R&D Systems™ Recombinant Human Active MAP3K8/Tpl2/COT Protein

Catalog No. 4586KS010
Click to view available options
Quantity:
10 μg
This item is not returnable. View return policy
This item is not returnable. View return policy

Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility.

The activity of COT is typically 860-1164 nmol/min/mg using MEK1 and ERK1 substrates and a myelin basic protein (MBP) substrate (see Activity Assay Protocol).

Specifications

Accession Number NM_005204
For Use With (Application) Bioactivity
Formulation Supplied in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.25 mM DTT, 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM PMSF, and 25% glycerol.
Gene ID (Entrez) 1326
Molecular Weight (g/mol) M.W. (Observed): 70 kDa
Quantity 10 μg
Source Spodoptera frugiperda, Sf 9 (baculovirus)-derived human MAP3K8/Tpl2/COT protein aa 30-397 Accession # NM_005204
Storage Requirements This product is stable at <= -70°C for up to 1 year from the date of receipt. For optimal storage, aliquot into smaller quantities after centrifugation and store (at recommended temperature. Avoid repeated freeze-thaw cycles.)
Gene Symbol MAP3K8
Conjugate Unconjugated
Purity or Quality Grade >70%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie™ Blue stain (at 5 μg / lane)
Protein MAP3K8/Tpl2/COT
Show More Show Less
Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.